UASSIGNED:相关研究表明,癌症患者接受辅助生殖是安全的。然而,在接受辅助生殖技术(ART)的女性中,关于癌症病史是否影响长期生殖结局的研究很少.在这项研究中,我们评估了接受ART治疗的恶性肿瘤患者的长期生殖结局,并探讨了恶性肿瘤病史对ART结局的影响.
UNASSIGNED:这项回顾性研究分析了2003年1月至2020年10月期间在福建省妇幼保健医院接受首次体外受精/卵胞浆内单精子注射(IVF/ICSI)周期的恶性肿瘤患者的临床结局与年龄匹配的健康不孕妇女的临床结局。我们评估了卵巢刺激结果,怀孕率,活产率,不良产科结局和分娩结局的风险。
UNASSIGNED:本研究纳入癌症组中59例有恶性肿瘤病史的患者进行数据分析。通过匹配,共有118名健康不孕妇女被纳入对照组。在年龄方面没有发现统计学上显著的关联,不孕的持续时间,BMI,或授精类型介于两组患者之间。甲状腺癌(45.8%)和妇科恶性肿瘤(44.07%)是本研究的主要癌症类型。窦卵泡计数(AFC)差异有统计学意义(12.00±7.86vs.14.90±8.71,P=0.033),卵巢刺激长度(9.98±2.68vs.11.42±2.43,P=0.033)和触发日子宫内膜厚度(10.16±3.11vs.10.84±2.17,P<0.001)。总促性腺激素剂量,回收的卵母细胞数量,受精率,卵裂率,优质胚胎率,肿瘤组的囊胚率和首次胚胎移植(ET)植入率均低于对照组(P>0.05)。每个ET周期的临床妊娠率没有显着差异(32%vs.40.39%,P=0.156),每个ET周期的活产率(27%vs.35.96%,P=0.119),每个ET周期的流产率(5%与4.43%,P=0.779),或每个ET周期的早产率(11.11%与17.80%,两组之间P=0.547)。此外,回归分析显示,恶性肿瘤病史不是生殖结局的危险因素.
未经评估:总的来说,有癌症史的女性使用ART受孕是可行的,其长期生殖结局与健康不孕女性相似。癌症病史不会减少获取的卵母细胞数量,增加不良产科结局的风险或影响分娩结局.
UNASSIGNED: Related studies have shown that it is safe for cancer patients to undergo assisted reproduction. However, studies on whether a history of cancer affects long-term reproductive outcomes in women who undergo assisted reproductive technology (ART) are scarce. In this study, we evaluated the long-term reproductive outcomes of patients with malignant tumors undergoing ART treatment and explored the impact of malignancy history on ART outcomes.
UNASSIGNED: This retrospective study analyzed the clinical outcomes of patients with malignant tumors undergoing their first in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) cycles compared with those of age-matched healthy infertile women at Fujian Maternity and Child Health Hospital between January 2003 and October 2020. We evaluated ovarian stimulation outcome, the pregnancy rate, the live birth rate, the risk of adverse obstetric outcomes and birth outcomes.
UNASSIGNED: This study included 59 patients in the cancer group for data analysis who had a history of malignancy. By matching, a total of 118 healthy infertile women were included in the control group. No statistically significant association was found in terms of age, duration of infertility, BMI, or insemination type between the two groups of patients. Thyroid cancer(45.8%) and gynecologic malignancies (44.07%) were the major cancer types in this study. There were statistically significant differences in the antral follicle count (AFC) (12.00 ± 7.86 vs. 14.90 ± 8.71, P=0.033), length of ovarian stimulation (9.98 ± 2.68 vs. 11.42 ± 2.43, P=0.033) and endometrial thickness on the trigger day (10.16 ± 3.11 vs. 10.84 ± 2.17, P<0.001) between the two groups. The total gonadotropin dose, number of oocytes retrieved, fertilization rate, cleavage rate, high-quality embryo rate, blastocyst rate and first-time embryo-transfer (ET) implantation rate were nonsignificantly lower in the cancer group than in the control group (P>0.05). There were no significant differences in the clinical pregnancy rate per ET cycle (32% vs. 40.39%, P=0.156), live birth rate per ET cycle (27% vs. 35.96%, P=0.119), miscarriage rate per ET cycle (5% vs. 4.43%, P=0.779), or preterm delivery rate per ET cycle (11.11% vs. 17.80%, P=0.547) between the two groups. Additionally, regression analysis showed that a history of malignancy was not a risk factor for reproductive outcomes.
UNASSIGNED: Overall, it is feasible for women with a history of cancer to conceive using ART is feasible and their long-term reproductive outcomes are similar to these of healthy infertile women. A history of cancer does not decrease the number of retrieved oocytes, increase the risk of adverse obstetric outcomes or affect birth outcomes.